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Antibodies obtained from rabbits against soluble yeast phosphofructokinase also react with the particulate 
yeast phosphofructokinase. Their effects on the activity of the soluble enzyme recognized as inactivation 
or slight activation depend on the specific immune response of an individual animal yielding antisera with 
different proportions of inactivating and activating antibodies. The availability of particulate 
phosphofructokinase to complex inactivating antibodies specifically allows a separation of activating and 
inactivating antibodies from each other by a simple extraction procedure. 
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1. INTRODUCTION 
Phosphofructokinase (EC 2.7.1.11) from yeast, 
a key enzyme of glucose catabolism [ 1,2], is com- 
posed of two kinds of subunits, LY andp, being pre- 
sent in a 1: 1 ratio and forming an octameric 
assembly [3,4]. It was deduced that the larger 
subunit LY does not participate in the catalytic pro- 
cess and the substrate binding sites being localized 
exclusively on the &subunits [5]. 
In addition to this well-known cytosolic enzyme 
the presence of a membrane-bound phospho- 
fructokinase was demonstrated in yeast [6]. This 
particulate enzyme is not inhibited by ATP but 
strongly inhibited by fructose 1,6-bisphosphate. 
With fructose 6-phosphate as well as with ATP the 
membrane-bound phosphofructokinase displays 
hyperbolic saturation curves; fructose 
2,6-bisphosphate does not activate the enzyme. 
Furthermore, the gene responsible for the deter- 
mination of the regulatory subunit of the soluble 
allosteric enzyme may be an essential determinant 
for the synthesis of the particulate enzyme [7,8]. 
In [9], immunization of rabbits with the soluble 
Abbreviations: PMSF, phenylmethylsulfonyl fluoride; 
EDTA, ethylenediaminetetraacetic acid, disodium salt 
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phosphofructokinase gave rise to distinct anti- 
bodies actually directed against he two subunits cy 
and p. Here, we deal with the interaction of an- 
tibodies produced by rabbits after immunization 
with soluble phosphofructokinase with the 
cytosolic and the membrane-bound enzyme. 
2. EXPERIMENTAL 
2.1. Enzymes and chemicals 
Baker’s yeast was purchased as Stellhefe I (ex- 
ponentially growing yeast on sugar substrates) 
from VEB Backhefe (Leipzig). ATP, AMP, 
NADH, fructose 6-phosphate and auxiliary en- 
zymes were products from Boehringer (Mann- 
heim). Polyethylene glycol 4000 and agarose were 
obtained from Serva (Heidelberg). Buffer 
substances were of analytical grade. Soluble 
phosphofructokinase was prepared from baker’s 
yeast as in [3]. 
2.2. Enzyme assays 
Phosphofructokinase activity was measured as 
in [ 11. Particulate phosphofructokinase was 
assayed by coupling the formation of fructose 
1,6-bisphosphate from fructose 6-phosphate and 
ATP in a membrane suspension with the aldolase 
Volume 155. number 1 FEBS LETTERS May 1983 
reaction and subsequent determination of triose 
phosphates: 0.5 ml membrane suspension (see 
below) were mixed with 1 ml assay buffer contain- 
ing 3 mM fructose 6-phosphate, 0.6 mM ATP, 
5 mM MgS04,5 mM (NH&Sod, 0.2 mM NADH, 
0.05 mM PMSF and 0.2 units of aldolase in 0.1 M 
imidazole-HCI (pH 7.15). After 10 min the 
samples were centrifuged at 10000 x g and 1 ml 
supernatant was analyzed by adding 0.25 units of 
glycerol l-phosphate dehydrogenase and 2.7 units 
of triose phosphate isomerase. 
2.3. Immunological methods 
For determination of antibody titers im- 
munodiffusion was done as in [lo] in 0.1 M 
sodium phosphate buffer (pH 7.5) and 1.5% 
agarose in the presence of 2.5% polyethylene 
glycol4000. Purified phosphofructokinase was us- 
ed as antigen at 1 mg/ml. 
2.4. Antibody preparation 
Phosphofructokinase (3 mg) was dialyzed 
against 50 mM sodium phosphate buffer (pH 7.0) 
containing 0.1 mM PMSF, 1 mM fructose 
6-phosphate, 5 mM 2-mercaptoethanol and 
0.5 mM EDTA. A final volume of 0.5 ml was 
emulsified with an equal volume of complete 
Freund’s adjuvant and injected i.m. at 2 sites in 
male rabbits of -2 kg. After 10 weeks a second 
and after 15 weeks a third S.C. injection of 0.5 mg 
enzyme in complete Freund’s adjuvant followed. 
One week later the antibody titer was - 1: 64. The 
serum was fractionated with ammonium sulphate 
at 45% saturation and the precipitate was submit- 
ted to DEAE-cellulose chromatography at pH 8.2 
in 50 mM sodium phosphate buffer. Protein which 
was not bound to DEAE-cellulose was concen- 
trated by ammonium sulphate precipitation and 
stored at 4°C in 0.1 M sodium phosphate buffer 
(pH 7.2) containing 2.5 M ammonium sulphate. 
Before use, the immunoglobulin solution was 
dialyzed and diluted to equal titers. 
2.5. Preparation of yeast cell membrane 
suspension 
Yeast cells were washed and disrupted by 
ultrasonication as in [ 111. Soluble phosphofruc- 
tokinase was removed from the 10000 x g pellet of 
the cell homogenate by repeated washing with 
50 mM sodium phosphate buffer (pH 7.0) contain- 
ing 0.1 mM PMSF and 0.5 mM EDTA. Each wash 
was checked by measuring phosphofructokinase 
activity in the 10000 x g supernatant. If they were 
free of soluble enzyme the pellet was suspended in 
an equal volume of washing buffer and designated 
as ‘membrane suspension’. As a control, whole 
yeast cells were washed and suspended in the same 
way. 
2.6. Treatment of yeast membranes with 
antibodies 
Membrane suspension (0.5 ml) was mixed with 
1 ml of antibodies of two rabbits A and B, diluted 
to a titer of 1: 128. After incubation for 1 h and 
centrifugation at 10000 x g 1 ml of the superna- 
tant was taken off and mixed again with 0.5 ml of 
a fresh membrane suspension. Incubation and cen- 
trifugation were done as before; the same process 
was repeated twice with 0.5 ml fresh membrane 
suspension for each cycle. After the fourth incuba- 
tion the supernatant was used as ‘membrane- 
treated anti-PFK I’. To discriminate unspecific an- 
tibody adsorption a second membrane treatment 
of antibodies was done: The 10000 x g pellet of the 
first incubation was washed and treated again with 
1 ml antibody solution for 1 h. This supernatant 
was designated as yeast ‘membrane anti-PFK II’. 
The precipitation titers of both the ‘membrane- 
treated anti-PFK I and II’ were brought to equal 
values by considering the dilution in the course of 
membrane treatment. 
In a control experiment whole yeast cell suspen- 
sion instead of disrupted cells was incubated with 
antibodies under the same conditions. Another 
control was done by treating the membrane 
suspension with purified immunoglobulins of a 
rabbit non-immunized with phosphofructokinase. 
3. RESULTS 
3.1. Interaction of antibodies against soluble 
phosphofructokinase with particulate 
phosphofnrctokinase 
Table 1 shows the activity of particulate 
phosphofructokinase in yeast membranes. In 
whole cells, practically no phosphofructokinase 
activity could be detected in the suspension buffer 
in the absence or presence of added im- 
munoglobulins. However, washed membrane 
pellets of ultrasonic homogenates, free of cytosolic 
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Table 1 3.2. Interaction of antibodies with soluble 
Activities of particulate phosphofructokinase in yeast 
membranes untreated and treated with antibodies 
against soluble phosphofructokinase 
phosphofructokinase 
Suspension of washed 
10000 x g pellet of 
Fructose Activity 
1,6-bisphosphate (t70) 
formed hmol) 
(.min-‘. 1.5 ml 
suspension-*) 
Disrupted yeast cells 
-treated with antibodies 
from rabbit A 
-treated twice with anti- 
bodies from rabbit A 
-treated with antibodies 
from rabbit A pre-treated 
4 times with disrupted 
yeast cells (anti-PFK I) 
-treated with antibodies 
from rabbit B 
-treated twice with anti- 
bodies from rabbit B 
-treated with antibodies 
from rabbit B pre-treated 
4 times with disrupted 
yeast cells (anti-PFK I) 
-treated with immuno- 
globulins from a non- 
immunized rabbit 
Whole yeast cells 
-treated with antibodies 
from rabbit A 
0.015 100 
0.009 60 
0.006 40 
0.012 80 
0.011 13 
0.009 60 
0.015 100 
0.014 93 
0.001 - 
0.002 - 
Purified soluble phosphofructokinase was in- 
cubated with anti-phosphofructokinase immuno- 
globulins, diluted to titers of 1: 128. Fig.1 shows 
the changing in activity obtained with antibodies 
from rabbits A and B and with immunoglobulins 
of a non-immunized rabbit. Obviously, immuno- 
globulins of the latter do not influence phospho- 
fructokinase activity. In the case of antibodies 
from rabbit A an inactivation of the enzyme was 
observed. If antibodies were diluted inactivation is 
delayed in a proportional manner (not shown). 
There is also no difference in the activities whether 
the samples are subjected to centrifugation or not. 
In contrast, antibodies of rabbit B exhibiting the 
same titer as antibodies from rabbit A do not ef- 
fect phosphofructokinase activity. 
To elucidate the action of membrane-treated 
anti-PFK with soluble phosphofructokinase the 
enzyme solution was incubated with membrane- 
20 40 60 80 100 120 
Incubation trme (mm 1 
phosphofructokinase, show the formation of fruc- 
tose 1,6-bisphosphate, obviously due to the 
presence of the particulate phosphofructokinase 
[6]. This activity decreased partially if the mem- 
branes are incubated with antibodies against the 
soluble phosphofructokinase. The extent of inhibi- 
tion depends on the source and the pretreatment of 
immunoglobulins with disrupted yeast cells. Im- 
munoglobulins from non-immunized rabbits do 
not display any effect on the activity of particulate 
phosphofructokinase. 
Fig. 1. Time dependence of phosphofructokinase activity 
during incubation with antibodies from different 
animals. Phosphofructokinase solution (0.1 ml, 
1 mg/ml) was incubated with 0.2 ml immunoglobulin 
solution from 2 immunized rabbits in 1.2 ml total vol. of 
50 mM sodium phosphate buffer (pH 7.0) containing 
0.1 mM PMSF and 0.5 mM EDTA. Aliquots of 0.1 ml 
were taken at appropriate times and phosphofructo- 
kinase activity was estimated. Activities are compared 
with a control in which immunoglobulin solution is 
replaced by 0.2 ml buffer: (H) immunoglobulin 
from a non-immunized rabbit; (.--+) 
immunoglobulin from immunized rabbit A; (~--0) 
immunoglobulin from immunized rabbit B. 
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incubation time I mm 1 
Fig.2. Time dependence of phosphofructokinase activity 
during incubation with yeast membrane-treated 
antibodies. Phosphofructokinase solution (0.1 ml, 
1 mg/ml) was incubated with 1 ml ‘membrane-treated 
anti-PFK I or II’ or with 1 ml immunoglobulin solution 
from a non-immunized rabbit, treated 4 times with yeast 
membranes. Final volume was 1.2 ml. Aliquots (0.1 ml) 
were tested for phosphofructokinase activity. Activities 
are compared with a control in which immunoglobulin 
solution is replaced by buffer: (H) membrane- 
treated immunoglobulins from a non-immunized rabbit; 
(M) membrane-treated anti-PFK I from rabbit A; 
(ti) membrane-treated anti-PFK II from rabbit A; 
(w) membrane-treated anti-PFK I from rabbit B; 
(ti) membrane-treated anti-PFK II from rabbit B. 
treated anti-PFK I or II, respectively, from the 
rabbits A and B or with membrane-treated im- 
munoglobulins of a non-immunized rabbit (fig.2). 
The membrane-treated immunoglobulins of the 
control animal do not show any effect on 
phosphofructokinase activity. Antibodies of rabbit 
A, causing an inactivation if they are not pre- 
treated with membranes, give rise to a slight in- 
crease of enzyme activity after treatment with yeast 
membranes. Under these conditions antibodies of 
rabbit B even cause a remarkable activation up to 
140% comparing with the control activity. The 
membrane-treated anti-PFK II of rabbit A and B 
exhibit an intermediate action being between the 
original and the 4-times membrane-treated an- 
tibodies. If the antibodies are treated with whole 
yeast cell suspensions instead of disrupted yeast 
cells their effects on phosphofructokinase activity 
are identical with those obtained with the original 
immunoglobulins. 
4. DISCUSSION 
Immunization of rabbits with purified cytosolic 
yeast phosphofructokinase yields antisera which 
differ in their effects on phosphofructokinase ac- 
tivity. The diverse action of antibody populations 
from rabbits A and B on soluble phosphofruc- 
tokinase can be explained by the presence of vary- 
ing ratios and different affinities of inhibiting, 
non-inhibiting and activating antibodies in these 
antisera [12]. If antibodies are directed against the 
2 subunits cy and ,& of the soluble enzyme, one 
could expect that the particulate phosphofruc- 
tokinase described in [6] should cross-react with 
these antibodies because one gene is assumed to be 
involved in the specification of both the particulate 
enzyme and the regulatory subunit of the soluble 
enzyme [7,8]. In fact, after treating disrupted yeast 
cells containing the particulate enzyme with im- 
munoglobulins from rabbits immunized with 
cytosolic phosphofructokinase the activity of the 
membrane-bound enzyme decreases, indicating the 
expected cross-reactivity (table 1). Moreover, by 
treatment of the immunoglobulins with yeast 
membranes inactivating antibodies are removed 
from the antibody mixture and the remaining frac- 
tions are able to activate the soluble phosphofruc- 
tokinase (rabbit B) or their inhibitory effect ceases 
(rabbit A). By considering also the control with 
non-disrupted cells and with membranes twice 
treated with antibodies the interaction of an- 
tibodies with the particulate phosphofructokinase 
seems to be specific. But if the common compo- 
nent of the soluble and the membrane-bound 
enzyme is the regulatory subunit of the cytosolic 
enzyme, it is surprising that anti-soluble phos- 
phofructokinase causes an inactivation of both 
types of enzymes. An inactivation may be expected 
if the antibodies bind preferentially to the active 
center of the enzyme. Because the particulate en- 
zyme and the P-subunit of the soluble enzyme (the 
nomenclature of cytosolic phosphofructokinase 
subunits is in accordance with [3,4,13] but in con- 
trast to [8]), on which the catalytic centers are 
assumed to be localized, are products of distinct 
genes the cross-reactivity of inactivating antibodies 
may be due to their interactions with conforma- 
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tional determinants located closely to the active 
center both in the membrane-bound and in the 
soluble enzyme. 
The activation of phosphofructokinase caused 
by membrane-treated antibodies has to be at- 
tributed to activating antibodies. A similar effect 
has been described for phosphofructokinase from 
rabbit skeletal muscle [14,15]. Due to the specific 
stability of the oligomeric structure of the yeast 
phosphofructokinase [3] the nature of its activa- 
tion remains to be elucidated. 
The possibility to remove inactivating antibodies 
from antisera containing both activating and in- 
hibiting antibodies may be a useful tool for further 
experiments. 
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